benzatropine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
atropine derivatives	333	86-13-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cogentin benztropine mesilate benzatropine benztropine tropine benzohydryl ether benztropine mesylate	A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine. Molecular weight: 307.44 Formula: C21H25NO CLOGP: 3.52 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 12.47 ALOGS: -5.41 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cogentin
benztropine mesilate
benzatropine
benztropine
tropine benzohydryl ether
benztropine mesylate

A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.

Molecular weight: 307.44
Formula: C21H25NO
CLOGP: 3.52
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 12.47
ALOGS: -5.41
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	mg	O
2	mg	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.21 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	29 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
March 5, 1954	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	354.95	20.15	225	7000	131664	50466235
Toxicity to various agents	161.70	20.15	174	7051	212325	50385574
Granulocytopenia	144.43	20.15	46	7179	5185	50592714
Schizophrenia	140.24	20.15	49	7176	7348	50590551
Psychotic disorder	135.88	20.15	65	7160	21747	50576152
Tardive dyskinesia	114.52	20.15	42	7183	7237	50590662
Neuroleptic malignant syndrome	87.50	20.15	39	7186	11091	50586808
Hallucination, auditory	79.27	20.15	36	7189	10692	50587207
Muscle rigidity	72.68	20.15	33	7192	9796	50588103
Paranoia	71.05	20.15	33	7192	10315	50587584
Extrapyramidal disorder	64.04	20.15	32	7193	11738	50586161
Agitation	57.55	20.15	53	7172	53331	50544568
Catatonia	56.70	20.15	21	7204	3715	50594184
Clonus	54.43	20.15	21	7204	4154	50593745
Oculogyric crisis	53.93	20.15	16	7209	1421	50596478
Sedation	53.02	20.15	40	7185	30570	50567329
Hyperreflexia	50.28	20.15	21	7204	5097	50592802
Akathisia	49.62	20.15	24	7201	8205	50589694
Ileus paralytic	47.95	20.15	19	7206	4031	50593868
Schizoaffective disorder	47.18	20.15	16	7209	2190	50595709
Cardiac arrest	45.75	20.15	58	7167	83593	50514306
Salivary hypersecretion	45.18	20.15	21	7204	6570	50591329
Drug interaction	44.59	20.15	92	7133	199529	50398370
Myocarditis	44.39	20.15	22	7203	7925	50589974
Drooling	44.03	20.15	17	7208	3367	50594532
Suicidal ideation	43.01	20.15	46	7179	55339	50542560
Dyskinesia	42.99	20.15	34	7191	27827	50570072
Hyperthermia	42.08	20.15	21	7204	7675	50590224
Dystonia	41.24	20.15	24	7201	11902	50585997
Tremor	41.06	20.15	65	7160	114838	50483061
Amaurosis	38.74	20.15	10	7215	530	50597369
Haemoglobin urine	35.11	20.15	7	7218	113	50597786
Encephalitis autoimmune	34.45	20.15	11	7214	1247	50596652
Cardio-respiratory arrest	33.70	20.15	40	7185	53852	50544047
Electrocardiogram QT prolonged	33.26	20.15	39	7186	51847	50546052
Treatment noncompliance	32.60	20.15	30	7195	30120	50567779
Abnormal behaviour	32.51	20.15	25	7200	19633	50578266
Blood prolactin increased	31.40	20.15	13	7212	3086	50594813
Aggression	30.93	20.15	25	7200	21091	50576808
Delusion	30.66	20.15	19	7206	10550	50587349
Psychiatric decompensation	30.38	20.15	10	7215	1248	50596651
Torsade de pointes	28.69	20.15	19	7206	11816	50586083
Mental status changes	26.18	20.15	29	7196	36243	50561656
Eosinophil count abnormal	25.77	20.15	7	7218	452	50597447
Impulsive behaviour	25.11	20.15	9	7216	1449	50596450
Red blood cells urine	25.00	20.15	7	7218	506	50597393
Suspected suicide	24.61	20.15	13	7212	5344	50592555
Confusional state	24.55	20.15	70	7155	185858	50412041
Toxic encephalopathy	24.25	20.15	13	7212	5502	50592397
Grandiosity	23.96	20.15	6	7219	281	50597618
Schizoaffective disorder bipolar type	23.57	20.15	5	7220	111	50597788
Mydriasis	23.22	20.15	16	7209	10611	50587288
Somnolence	23.09	20.15	61	7164	154924	50442975
Facial paralysis	22.86	20.15	17	7208	12698	50585201
Pneumonia aspiration	22.74	20.15	25	7200	30979	50566920
Areflexia	22.67	20.15	10	7215	2770	50595129
Death	22.56	20.15	99	7126	325280	50272619
Hallucination	21.85	20.15	30	7195	46627	50551272
Unresponsive to stimuli	21.28	20.15	24	7201	30585	50567314
Arthralgia	21.10	20.15	19	7206	438683	50159216
Parkinsonism	20.95	20.15	14	7211	8833	50589066
Hypersensitivity	20.79	20.15	3	7222	215158	50382741
Device leakage	20.77	20.15	12	7213	5866	50592033
Pain	20.47	20.15	32	7193	578871	50019028
Intentional overdose	20.45	20.15	34	7191	62470	50535429
Mental disorder	20.19	20.15	20	7205	21971	50575928

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	253.08	20.08	209	8381	90037	29475900
Granulocytopenia	205.52	20.08	74	8516	5920	29560017
Myocarditis	162.32	20.08	74	8516	10882	29555055
Tardive dyskinesia	140.23	20.08	54	8536	5204	29560733
Toxicity to various agents	135.73	20.08	206	8384	173455	29392482
Neuroleptic malignant syndrome	118.76	20.08	68	8522	16080	29549857
Schizophrenia	102.45	20.08	46	8544	6519	29559418
Extrapyramidal disorder	83.35	20.08	47	8543	10784	29555153
Psychotic disorder	82.81	20.08	59	8531	20295	29545642
Cogwheel rigidity	81.34	20.08	25	8565	1218	29564719
Hallucination, auditory	69.43	20.08	40	8550	9553	29556384
Hyperprolactinaemia	68.34	20.08	22	8568	1248	29564689
Agitation	67.91	20.08	79	8511	51225	29514712
Anticholinergic syndrome	67.16	20.08	20	8570	874	29565063
Dystonia	66.19	20.08	39	8551	9710	29556227
Tremor	64.00	20.08	92	8498	73446	29492491
Drug abuse	62.42	20.08	95	8495	79788	29486149
Sedation	60.73	20.08	46	8544	17359	29548578
Drug interaction	58.06	20.08	156	8434	197229	29368708
Device leakage	56.13	20.08	27	8563	4468	29561469
Galactorrhoea	53.42	20.08	14	8576	380	29565557
Drooling	49.78	20.08	22	8568	2999	29562938
Akathisia	48.48	20.08	28	8562	6714	29559223
Product dose omission issue	45.69	20.08	92	8498	96291	29469646
Syringe issue	45.08	20.08	22	8568	3756	29562181
Head titubation	42.65	20.08	11	8579	280	29565657
Restlessness	41.45	20.08	41	8549	22104	29543833
Treatment noncompliance	40.14	20.08	42	8548	24185	29541752
Muscle rigidity	39.92	20.08	28	8562	9383	29556554
Parkinsonism	38.90	20.08	25	8565	7253	29558684
Inappropriate schedule of product administration	37.70	20.08	55	8535	44417	29521520
Abnormal behaviour	36.37	20.08	39	8551	23088	29542849
Eosinophilic pleural effusion	35.97	20.08	9	8581	202	29565735
Priapism	35.94	20.08	20	8570	4468	29561469
Schizoaffective disorder	35.60	20.08	13	8577	1079	29564858
Sinus tachycardia	34.11	20.08	31	8559	15038	29550899
Dyskinesia	33.63	20.08	35	8555	20026	29545911
Catatonia	33.31	20.08	19	8571	4449	29561488
Antipsychotic drug level increased	33.14	20.08	17	8573	3226	29562711
Dystonic tremor	31.58	20.08	8	8582	189	29565748
Troponin increased	31.42	20.08	24	8566	9159	29556778
Drug level increased	30.10	20.08	32	8558	18755	29547182
Sedation complication	30.05	20.08	12	8578	1270	29564667
Aggression	28.74	20.08	43	8547	35498	29530439
Delirium	28.13	20.08	45	8545	39352	29526585
Blood prolactin increased	27.97	20.08	12	8578	1522	29564415
Blood pH decreased	27.20	20.08	13	8577	2120	29563817
Antipsychotic drug level decreased	27.05	20.08	10	8580	859	29565078
Parasomnia	26.61	20.08	8	8582	361	29565576
Haemophagocytic lymphohistiocytosis	26.54	20.08	23	8567	10481	29555456
Device malfunction	26.43	20.08	21	8569	8486	29557451
Somnolence	26.24	20.08	73	8517	93882	29472055
Blood creatine phosphokinase increased	25.75	20.08	44	8546	40600	29525337
Mental status changes	25.07	20.08	40	8550	34887	29531050
Gynaecomastia	24.92	20.08	20	8570	8197	29557740
Needle issue	24.81	20.08	16	8574	4667	29561270
Cerebral amyloid angiopathy	24.78	20.08	6	8584	117	29565820
Faecaloma	23.86	20.08	15	8575	4187	29561750
Delusion	23.30	20.08	22	8568	11194	29554743
Agranulocytosis	23.08	20.08	29	8561	20311	29545626
Lethargy	22.91	20.08	40	8550	37540	29528397
Globulins decreased	22.25	20.08	6	8584	182	29565755
Paranoia	21.72	20.08	20	8570	9857	29556080
Serotonin syndrome	21.53	20.08	26	8564	17486	29548451
Device breakage	20.39	20.08	10	8580	1724	29564213
Febrile neutropenia	20.26	20.08	4	8586	112236	29453701

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	623.66	18.45	448	12781	223966	64261537
Granulocytopenia	357.75	18.45	118	13111	10322	64475181
Toxicity to various agents	276.56	18.45	355	12874	363158	64122345
Tardive dyskinesia	225.83	18.45	81	13148	9097	64476406
Neuroleptic malignant syndrome	184.86	18.45	94	13135	24902	64460601
Myocarditis	180.46	18.45	82	13147	16961	64468542
Schizophrenia	175.27	18.45	71	13158	11097	64474406
Psychotic disorder	153.72	18.45	93	13136	34485	64451018
Agitation	123.45	18.45	119	13110	88248	64397255
Hallucination, auditory	103.26	18.45	56	13173	16883	64468620
Muscle rigidity	98.88	18.45	55	13174	17418	64468085
Drug interaction	95.09	18.45	221	13008	361862	64123641
Extrapyramidal disorder	90.51	18.45	54	13175	19498	64466005
Tremor	89.67	18.45	130	13099	148100	64337403
Catatonia	84.87	18.45	38	13191	7582	64477921
Dystonia	84.47	18.45	51	13178	18814	64466689
Sedation	79.93	18.45	67	13162	41395	64444108
Device leakage	75.74	18.45	36	13193	8230	64477273
Cogwheel rigidity	73.25	18.45	26	13203	2827	64482676
Schizoaffective disorder	71.04	18.45	22	13207	1565	64483938
Paranoia	67.57	18.45	42	13187	16310	64469193
Drug abuse	67.14	18.45	107	13122	132267	64353236
Drooling	63.98	18.45	28	13201	5291	64480212
Oculogyric crisis	60.90	18.45	22	13207	2516	64482987
Product dose omission issue	60.14	18.45	127	13102	194620	64290883
Treatment noncompliance	57.74	18.45	57	13172	43425	64442078
Hyperprolactinaemia	57.49	18.45	24	13205	4041	64481462
Galactorrhoea	55.81	18.45	22	13207	3197	64482306
Salivary hypersecretion	54.87	18.45	33	13196	12080	64473423
Ileus paralytic	54.58	18.45	29	13200	8386	64477117
Syringe issue	52.98	18.45	23	13206	4263	64481240
Dyskinesia	52.98	18.45	52	13177	39336	64446167
Mental status changes	52.94	18.45	64	13165	61098	64424405
Parkinsonism	52.12	18.45	34	13195	14339	64471164
Akathisia	51.22	18.45	31	13198	11479	64474024
Restlessness	50.69	18.45	51	13178	39734	64445769
Aggression	49.49	18.45	54	13175	46178	64439325
Cardio-respiratory arrest	47.76	18.45	78	13151	98315	64387188
Hyperreflexia	47.39	18.45	25	13204	7123	64478380
Arthralgia	43.80	18.45	18	13211	442242	64043261
Antipsychotic drug level increased	42.99	18.45	21	13208	5094	64480409
Abnormal behaviour	42.65	18.45	43	13186	33579	64451924
Death	42.18	18.45	203	13026	482502	64003001
Eosinophilic pleural effusion	41.91	18.45	10	13219	263	64485240
Device malfunction	41.41	18.45	32	13197	17601	64467902
Delusion	40.81	18.45	32	13197	17982	64467521
Blood prolactin increased	40.59	18.45	18	13211	3510	64481993
Clonus	39.60	18.45	21	13208	6046	64479457
Anticholinergic syndrome	38.56	18.45	16	13213	2653	64482850
Priapism	38.55	18.45	18	13211	3952	64481551
Inappropriate schedule of product administration	37.98	18.45	68	13161	92218	64393285
Diarrhoea	37.07	18.45	57	13172	722647	63762856
Gynaecomastia	36.96	18.45	20	13209	5996	64479507
Suicidal ideation	35.37	18.45	55	13174	66487	64419016
Anaemia	34.98	18.45	17	13212	378663	64106840
Dystonic tremor	34.35	18.45	8	13221	189	64485314
Delirium	33.76	18.45	55	13174	69139	64416364
Pain	33.07	18.45	39	13190	553472	63932031
Hallucination	33.03	18.45	56	13173	72732	64412771
Psychiatric decompensation	33.02	18.45	14	13215	2449	64483054
Intentional overdose	32.90	18.45	63	13166	89881	64395622
Suspected suicide	32.67	18.45	21	13208	8633	64476870
Somnolence	31.88	18.45	103	13126	203542	64281961
Haemoglobin urine	31.86	18.45	7	13222	126	64485377
Sinus tachycardia	31.70	18.45	36	13193	32152	64453351
Needle issue	31.35	18.45	21	13208	9251	64476252
Respiratory arrest	31.29	18.45	46	13183	52939	64432564
Head titubation	30.73	18.45	10	13219	835	64484668
Joint swelling	30.63	18.45	4	13225	215378	64270125
Confusional state	30.53	18.45	120	13109	261024	64224479
Encephalitis autoimmune	29.62	18.45	12	13217	1872	64483631
Blood creatine phosphokinase increased	29.18	18.45	47	13182	58511	64426992
Persecutory delusion	28.87	18.45	15	13214	4143	64481360
Mania	28.68	18.45	25	13204	16261	64469242
Amaurosis	28.66	18.45	10	13219	1034	64484469
Agranulocytosis	28.28	18.45	37	13192	38192	64447311
Cardiac arrest	27.89	18.45	82	13147	153982	64331521
Dysarthria	27.34	18.45	46	13183	59360	64426143
Parasomnia	27.04	18.45	8	13221	487	64485016
Drug level increased	26.71	18.45	34	13195	34162	64451341
Leukopenia	26.65	18.45	62	13167	101180	64384323
Tachycardia	24.62	18.45	77	13152	149502	64336001
Unresponsive to stimuli	24.50	18.45	40	13189	50353	64435150
Mental disorder	23.40	18.45	28	13201	26417	64459086
Haemophagocytic lymphohistiocytosis	23.21	18.45	23	13206	17586	64467917
Antipsychotic drug level above therapeutic	23.04	18.45	10	13219	1851	64483652
Hypersensitivity	22.91	18.45	6	13223	196446	64289057
Dyspnoea	22.62	18.45	74	13155	718600	63766903
Gait disturbance	22.48	18.45	82	13147	172073	64313430
Mydriasis	22.06	18.45	21	13208	15291	64470212
Hyperthermia	21.78	18.45	21	13208	15529	64469974
Oedema peripheral	21.70	18.45	8	13221	210309	64275194
Eosinophil count abnormal	21.50	18.45	7	13222	585	64484918
Cerebral amyloid angiopathy	21.10	18.45	6	13223	317	64485186
Overdose	20.83	18.45	76	13153	159490	64326013
Red blood cells urine	20.79	18.45	7	13222	650	64484853
Rhabdomyolysis	20.75	18.45	53	13176	91673	64393830
White blood cell count increased	20.26	18.45	43	13186	65971	64419532
Blood pH decreased	19.95	18.45	12	13217	4390	64481113
Headache	19.95	18.45	50	13179	529417	63956086
Pneumonia aspiration	19.83	18.45	40	13189	59231	64426272
Lethargy	19.69	18.45	45	13184	72549	64412954
Disease progression	19.27	18.45	3	13226	141677	64343826
Hallucination, visual	19.14	18.45	26	13203	27808	64457695
Mental impairment	19.09	18.45	20	13209	16323	64469180
Muscle contracture	18.61	18.45	9	13220	2136	64483367

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N04AC01	NERVOUS SYSTEM ANTI-PARKINSON DRUGS ANTICHOLINERGIC AGENTS Ethers of tropine or tropine derivatives
FDA MoA	N0000000207	Histamine Receptor Antagonists
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
CHEBI has role	CHEBI:48407	antiparkinson agent
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:50370	parasympatholytics
CHEBI has role	CHEBI:66956	antidyskinetic agent
CHEBI has role	CHEBI:146270	oneirogens
CHEBI has role	CHEBI:149553	anticoronaviral drug
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018765	Dopamine Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D010276	Parasympatholytics
MeSH PA	D018373	Peripheral Nervous System Agents
FDA EPC	N0000175750	Antihistamine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Postencephalitic parkinsonism	indication	19972008	DOID:14332
Parkinsonism	indication	32798002
Parkinson's disease	indication	49049000	DOID:14330
Extrapyramidal disease	indication	76349003
Arteriosclerotic Parkinsonism	indication
Urinary tract obstruction	contraindication	7163005	DOID:5200
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of autonomic nervous system	contraindication	15241006
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Shigellosis	contraindication	36188001
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Dysuria	contraindication	49650001
Paralytic ileus	contraindication	55525008	DOID:8442
Ulcerative colitis	contraindication	64766004	DOID:8577
Hiatal hernia	contraindication	84089009	DOID:12642
Open-angle glaucoma	contraindication	84494001	DOID:1067
Kidney disease	contraindication	90708001	DOID:557
Thyrotoxicosis	contraindication	90739004	DOID:7997
Myasthenia gravis	contraindication	91637004	DOID:437
Tardive dyskinesia	contraindication	102449007
Dysentery	contraindication	111939009
Gastrointestinal obstruction	contraindication	126765001
Bleeding	contraindication	131148009
Gastroesophageal reflux disease	contraindication	235595009	DOID:8534
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Fever	contraindication	386661006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Pseudomembranous enterocolitis	contraindication	397683000
Gastric ulcer	contraindication	397825006	DOID:10808
Disorder of coronary artery	contraindication	414024009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.86	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Ki	9.64	WOMBAT-PK	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.23	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		IC50	4.62	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.86	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	8.16	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.90	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	7.50	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.89	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.52	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.65	DRUG MATRIX
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	8.96	WOMBAT-PK
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.93	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Ki	8.85	WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	8.96	WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN	ANTAGONIST	Ki	8.96	WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN	ANTAGONIST	Ki	8.55	WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.24	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Kd	7.25	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.59	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.69	DRUG MATRIX
Sodium-dependent neutral amino acid transporter B(0)AT1	Transporter	Q695T7	S6A19_HUMAN	INHIBITOR	IC50	4.36	IUPHAR
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.39	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.95	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	6.85	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR		ACM2_RAT		Ki	8.59	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR		ACM1_RAT		Ki	9.23	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		Ki	5.29	CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		Ki	6.93	CHEMBL

External reference:

ID	Source
D00778	KEGG_DRUG
132-17-2	SECONDARY_CAS_RN
1424	RXNORM
C0005098	UMLSCUI
CHEBI:3048	CHEBI
CXQ	PDB_CHEM_ID
CHEMBL1201203	ChEMBL_ID
CHEMBL1200383	ChEMBL_ID
DB00245	DRUGBANK_ID
7601	IUPHAR_LIGAND_ID
1201549	PUBCHEM_CID
3130	MMSL
4264	MMSL
563	MMSL
d00175	MMSL
001647	NDDF
004667	NDDF
4017824	VANDF
4019630	VANDF
D001590	MESH_DESCRIPTOR_UI
292	INN_ID
29527005	SNOMEDCT_US
372846002	SNOMEDCT_US
77390008	SNOMEDCT_US
1NHL2J4X8K	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9233	INJECTION	1 mg	INTRAMUSCULAR	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9729	INJECTION	1 mg	INTRAMUSCULAR	ANDA	14 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9729	INJECTION	1 mg	INTRAMUSCULAR	ANDA	14 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2433	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2434	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2435	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2437	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2438	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2439	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8210	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8211	TABLET	1 mg	ORAL	ANDA	16 sections
benztropine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8352	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1080	TABLET	0.50 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1081	TABLET	1 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1082	TABLET	2 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6788	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6789	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6790	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-606	TABLET	0.50 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-607	TABLET	1 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-608	TABLET	2 mg	ORAL	ANDA	15 sections
benztropine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10858-011	INJECTION	1 mg	INTRAMUSCULAR	ANDA	1 sections
Benztropine Mesylate Injection, USP	HUMAN PRESCRIPTION DRUG LABEL	1	14789-300	INJECTION	1 mg	PARENTERAL	ANDA	11 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	17478-012	INJECTION	1 mg	INTRAVENOUS	NDA authorized generic	16 sections
BENZTROPINE MESYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-286	TABLET	2 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-218	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-219	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-220	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	43353-580	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	43353-707	TABLET	0.50 mg	ORAL	ANDA	16 sections